Physician profile
John Mak
NPI 1417924168
$12,115.10
in general payments reported to CMS, 2019-2025
48 companies · $2,053 in 2025
The $2,053 reported for 2025 was more than what 79% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,328 · 2020: $1,169 · 2021: $2,502 · 2022: $1,585 · 2023: $1,002 · 2024: $1,476 · 2025: $2,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,436 · Travel and Lodging: $95.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,435.70 |
| Travel and Lodging | $95.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,640.42 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16, General - Therapies |
| Vertos Medical, INC. | $1,006.32 | 2019-2024 | Mild Device Kit |
| Scilex Pharmaceuticals INC. | $1,000.36 | 2019-2024 | Ztlido |
| Mml US, INC. | $905.23 | 2021-2024 | Reactiv8 |
| Collegium Pharmaceutical, INC. | $853.14 | 2019-2025 | Belbuca |
| Saluda Medical Americas, INC. | $831.61 | 2022-2025 | Evoke, Evoke Scs |
| Abbott Laboratories | $759.00 | 2019-2025 | Eterna, Proclaim |
| Globus Medical, INC. | $485.39 | 2025 | Senza |
| Nevro Corp. | $447.03 | 2019-2023 | Senza |
| Averitas Pharma INC. | $412.77 | 2023-2025 | Qutenza |
| Si-Bone, INC. | $387.09 | 2019-2021 | |
| Vertiflex, INC. | $359.09 | 2019 | |
| Biotronik Nro, INC. | $290.05 | 2024-2025 | Prospera |
| Medtronic USA, INC. | $280.20 | 2019-2020 | |
| Horizon Therapeutics Plc | $226.59 | 2019-2022 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $195.27 | 2020-2021 | |
| Grt US Holding, INC. | $185.74 | 2021-2022 | |
| Pfizer INC. | $178.32 | 2019-2021 | |
| Spinal Elements, INC. | $170.57 | 2024 | |
| Nuvasive, INC. | $132.49 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.41 | 2021-2025 | Relistor |
| Medtronic, INC. | $114.50 | 2021-2025 | Inceptiv |
| Protega Pharmaceutials INC | $110.91 | 2023 | Roxybond |
| Spr Therapeutics, INC | $107.11 | 2021-2025 | Sprint Pns System |
| Almatica Pharma LLC | $93.95 | 2021 | |
| Azurity Pharmaceuticals, INC. | $84.76 | 2023-2025 | Horizant, Horizant |
| Fidia Pharma USA INC. | $70.06 | 2019-2024 | Hyalgan, Hymovis, Triluron |
| Zimmer Biomet Holdings, INC. | $64.27 | 2023-2025 | Gel-One Cross-Linked Hyaluronate |
| Stimwave Technologies Incorporated | $56.00 | 2021 | |
| Ibsa Pharma INC. | $54.44 | 2021-2023 | Tirosint, Licart |
| Depuy Synthes Sales INC. | $52.19 | 2020-2025 | Monovisc, Orthovisc |
| Vertex Pharmaceuticals Incorporated | $49.23 | 2024-2025 | |
| Mdd US Operations, LLC | $40.34 | 2019-2020 | |
| Uswm, LLC | $39.68 | 2021-2022 | |
| Nalu Medical, INC. | $38.47 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $32.00 | 2023 | Exparel, Zilretta, Iovera |
| Ambu INC. | $30.72 | 2022 | |
| Assertio Therapeutics, INC. | $27.58 | 2020 | |
| Vertical Pharmaceuticals, LLC | $27.09 | 2019 | |
| Spinal Simplicity, LLC | $23.65 | 2025 | Ha Minuteman G3-R |
| Valinor Pharma, LLC | $19.09 | 2025 | Movantik |
| Bioventus LLC | $18.41 | 2021 | |
| Daiichi Sankyo INC. | $18.08 | 2019 | |
| Virtus Pharmaceuticals LLC | $17.80 | 2025 | Levorphanol Tartrate |
| Tersera Therapeutics LLC | $14.64 | 2022 | |
| Zyla Life Sciences, INC. | $13.67 | 2020 | |
| Pacira Therapeutics, INC. | $11.42 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.